Abstract
Drug compounds including memantine moieties are an important group of biologically active agents for different pathologies, including the Alzheimer’s disease. In the present study, a series of memantine derivatives incorporating amino acid residues have been synthesized and their neuroprotective in vitro evaluation in respect of the Alzheimer’s disease, involving the effects on the resistance to Aβ toxicity, excitotoxicity, oxidative stress, hypoxia, and neuroinflammation has been studied. The cytotoxicities of the compounds were detected by CPE assay. TC50 and IC50 were determined using Reed and Muench method. Solubility and distribution were measured using a shake-flask method. Permeability of the compounds was studied using Franz diffusion cell and Permeapad™ barrier. These compounds displayed apparent multi-neuroprotective effects against copper-triggered Aβ toxicity, glutamate-induced excitotoxicity, and oxidative and hypoxic injuries. They also showed the ability to inhibit the inflammatory cytokine release from the activated microglia and potential anti-neuroinflammatory effects. Especially, two most promising compounds H-4-F-Phe-memantine and H-Tyr-memantine demonstrated the equivalent functional bioactivities in comparison with the positive control memantine hydrochloride. Higher solubility in muriatic buffer than in phosphate buffer was detected. The distribution coefficients showed the optimal lipophilicity for compounds. The presented results propose new class of memantine derivatives as potential drug compounds. Based on the experimental results, the correlations have been obtained between the biological, physicochemical parameters and structural descriptors. The correlation equations have been proposed to predict the properties of new memantine derivatives knowing only the structural formula.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- NMDA:
-
N-Methyl-d-aspartate
- NMDARs:
-
N-Methyl-d-aspartate receptors
- AD:
-
Alzheimer’s disease
- L-DOPA:
-
L-3,4-Dihydroxyphenylalanine
- TBTU:
-
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylamonium tetrafluoroborate
- DIPEA:
-
N,N-Diisopropylethylamine
- DMAP:
-
4-(Dimethylamino)pyridine
References
ACD/ChemSketch program. https://eduinf.waw.pl/che/inne/prgchem/pages/chsk_eng.pdf
Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979) Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135(3):216–223. https://doi.org/10.1192/bjp.135.3.216
Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJ (2014) Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002745.pub4
Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76:27–50. https://doi.org/10.1016/j.neuropharm.2013.07.004
Andrés A, Rosés M, Ràfols C, Bosch E, Espinosa S, Segarra V, Huerta JM (2015) Setup and validation of shake-flask procedures for the determination of partition coefficients (log P) from low drug amounts. Eur J Pharm Sci 76:181–191. https://doi.org/10.1016/j.ejps.2015.05.008
Arciniegas DB, Frey KL, Anderson CA, Brousseau KM, Harris SN (2004) Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy. Brain Inj 18(12):1309–1318. https://doi.org/10.1080/02699050410001720130
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer’sdisease. Lancet 377(9770):1019–1031. https://doi.org/10.1016/S0140-6736(10)61349-9
Borodin VA, Kozlovsky EV, Vasilev VP (1982) Computer analysis of the results of calorimetric measurements in study on complex equilibriums in solutions. Russian J Inorganic Chem 27:2169–2172
Chiang K, Koo EH (2014) Emerging therapeutics for Alzheimer’s disease. Annu Rev Pharmacol Toxicol 54:381–405. https://doi.org/10.1146/annurev-pharmtox-011613-135932
Davies WL, Grunert RR, Haff RF, Mcgahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC, Hoffmann CE (1964) Antiviral activity of 1-adamantanamine (Amantadine). Science 144(3620):862–863. https://doi.org/10.1126/science.144.3620.862
Di Cagno M, Bibi HA, Bauer-Brandl A (2015) New biomimetic barrier PermeapadTM for efficient investigation of passive permeability of drugs. Eur J Pharm Sci 73:29–34. https://doi.org/10.1016/j.ejps.2015.03.019
Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF (2015) Vascular dysfunction in the pathogenesis of Alzheimer’s disease—a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis 82:593–606. https://doi.org/10.1016/j.nbd.2015.08.014
Di Marco B, Bonaccorso CM, Aloisi E, Antoni S, Catania MV (2016) Neuro-inflammatory mechanisms in developmental disorders associated with intellectual disability and autism spectrum disorder: a neuro-immune perspective. CNS Neurol Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 15(4):448–463. https://doi.org/10.2174/1871527315666160321105039
Di L, Kerns EH (2015) Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization. Academic press NY
Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51(1):7–62
Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM (2007) Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimer’s Dementia 3(1):7–17. https://doi.org/10.1016/j.jalz.2006.10.004
Faller P (2009) Copper and zinc binding to amyloid-β: coordination, dynamics, aggregation. Reactivity Metal-Ion Trans ChemBioChem 10(18):2837–2845. https://doi.org/10.1002/cbic.200900321
Gamdzyk M, Ziembowicz A, Bratek E, Salinska E (2016) Combining hypobaric hypoxia or hyperbaric oxygen postconditioning with memantine reduces neuroprotection in 7-day-old rat hypoxia-ischemia. Pharmacol Rep 68(5):1076–1083. https://doi.org/10.1016/j.pharep.2016.06.009
Giuffrida ML, Grasso G, Ruvo M, Pedone C, Saporito A, Marasco D, Pignataro B, Cascio C, Copani A, Rizzarelli E (2007) Aβ (25–35) and its C-and/or N-blocked derivatives: copper driven structural features and neurotoxicity. J Neurosci Res 85(3):623–633. https://doi.org/10.1002/jnr.21135
Heiss WD, Szelies B, Kessler J, Herholz K (1991) Abnormalities of energy metabolism in Alzheimer’s disease studied with PET a. Ann N Y Acad Sci 640(1):65–71. https://doi.org/10.1111/j.1749-6632.1991.tb00192.x
Higuchi T (1965) A phase solubility technique. Adv Anal Chem Instrum 4:117–211
Hu J, Zhao TZ, Chu WH, Luo CX, Tang WH, Yi L, Feng H (2010) Protective effects of 20-hydroxyecdysone on CoCl2-induced cell injury in PC12 cells. J Cell Biochem 111(6):1512–1521. https://doi.org/10.1002/jcb.22877
Hubsher G, Haider M, Okun MS (2012) Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78(14):1096–1099. https://doi.org/10.1212/WNL.0b013e31824e8f0d
Johnson JW, Kotermanski SE (2006) Mechanism of action of memantine. Curr Opin Pharmacol 6(1):61–67. https://doi.org/10.1016/j.coph.2005.09.007
Kim JH, Lee HW, Hwang J, Kim J, Lee MJ, Han HS, Lee WH, Suk K (2012) Microglia-inhibiting activity of Parkinson’s disease drug amantadine. Neurobiol Aging 33(9):2145–2159. https://doi.org/10.1016/j.neurobiolaging.2011.08.011
Knorr R, Trzeciak A, Bannwarth W, Gillessen D (1989) New coupling reagents in peptide chemistry. Tetrahedron Lett 30(15):1927–1930
Korenman IM (1977) Ekstraktsiya v analize organicheskikh veshchestv. Extraction in the analysis of organic compounds. Moscow, Khimiya, pp 78–84
Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91–104
Leon R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev 33(1):139–189. https://doi.org/10.1002/med.20248
Liang GD, Zhang YW, Lin DE (2010) Synthesis of memantine derivatives. Chinese J Synthetic Chem 4:38
Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discovery 5(2):160. https://doi.org/10.1038/nrd1958
Liu R, Wu CX, Zhou D, Yang F, Tian S, Zhang L, Zhang TT, Du GH (2012) Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis. BMC medicine 10(1):105. https://doi.org/10.1186/1741-7015-10-105
Liu QS, Jiang HL, Wang Y, Wang LL, Zhang JX, He CH, Shao S, Zhang TT, Xing JG, Liu R (2018) Total flavonoid extract from Dracoephalum moldavica L. attenuates β-amyloid-induced toxicity through anti-amyloidogenesic and neurotrophic pathways. Life Sci 193:214–225. https://doi.org/10.1016/j.lfs.2017.10.041
Makarewicz D, Sulejczak D, Duszczyk M, Małek M, Słomka M, Lazarewicz JW (2014) Delayed preconditioning with NMDA receptor antagonists in a rat model of perinatal asphyxia. Folia Neuropathol 52(3):270–284. https://doi.org/10.5114/fn.2014.45568
Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430(7000):631–639. https://doi.org/10.1038/nature02621
Müller T, Kuhn W, Möhr JD (2019) Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia. Expert Opin Pharmacother 20(10):1181–1187. https://doi.org/10.1080/14656566.2019.1612365
Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K (1996) The amyloid precursor protein of Alzheimer’s disease in the reduction of copper (II) to copper (I). Science 271(5254):1406–1409. https://doi.org/10.1126/science.271.5254.1406
Pan X, Kaminga AC, Wen S, Wu X, Acheampong K, Liu A (2019) Dopamine and dopamine receptors in Alzheimer’s disease: a systematic review and network meta-analysis. Front Aging Neurosci 11:175. https://doi.org/10.3389/fnagi.2019.00175
Parfenova H, Basuroy S, Bhattacharya S, Tcheranova D, Qu Y, Regan RF, Leffler CW (2006) Glutamate induces oxidative stress and apoptosis in cerebral vascular endothelial cells: contributions of HO-1 and HO-2 to cytoprotection. Am J Physiol-Cell Physiol 290(5):C1399–C1410. https://doi.org/10.1152/ajpcell.00386.2005
Parsons CG, Stöffler A, Danysz W (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53(6):699–723. https://doi.org/10.1016/j.neuropharm.2007.07.013
Perlovich GL, Volkova TV (2018) Sublimation thermodynamics aspects of adamantane and memantine derivatives of sulfonamide molecular crystals. Phys Chem Chem Phys 20(30):19784–19791. https://doi.org/10.1039/C8CP03716G
Perlovich GL, Ryzhakov AM, Tkachev VV, Proshin AN (2015) Adamantane derivatives of sulfonamide molecular crystals: structure, sublimation thermodynamic characteristics, molecular packing, and hydrogen bond networks. CrystEngComm 17(4):753–763. https://doi.org/10.1039/C4CE02076F
Perlovich GL, Volkova TV, Sharapova AV, Kazachenko VP, Strakhova NN, Proshin AN (2016) Adamantane derivatives of sulfonamides: sublimation, solubility, solvation and transfer processes in biologically relevant solvents. Phys Chem Chem Phys 18(13):9281–9294. https://doi.org/10.1039/C6CP00379F
Po HN, Senozan NM (2001) The Henderson-Hasselbalch equation: its history and limitations. J Chem Educ 78(11):1499–1503. https://doi.org/10.1021/ed078p1499
Raevsky OA, Grigor’ev VJ, Trepalin SV (1999) HYBOT program package. Registration by Russian State Patent Agency (990090)
Ramakrishnan MA (2016) Determination of 50% endpoint titer using a simple formula. World J Virol 5(2):85. https://doi.org/10.5501/wjv.v5.i2.85
Rogawski MA, Wenk GL (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev 9(3):275–308. https://doi.org/10.1111/j.1527-3458.2003.tb00254.x
Saganuwan SA (2011) A modified arithmetical method of Reed and Muench for determination of a relatively ideal median lethal dose (LD50). Afr J Pharmacy Pharmacol 5(12):1543–1546. https://doi.org/10.5897/AJPP2019.5070
Sawikr Y, Yarla NS, Peluso I, Kamal MA, Aliev G, Bishayee A (2017) Neuroinflammation in Alzheimer’s disease: the preventive and therapeutic potential of polyphenolic nutraceuticals. Adv Protein Chem Struct Biol 108:33–57. https://doi.org/10.1016/bs.apcsb.2017.02.001
Scatton B, Cheramy A, Besson MJ, Glowinski J (1970) Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol 13(1):131–133
Schmitt HP (2005) On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease. Med Hypotheses 65(2):259–265. https://doi.org/10.1016/j.mehy.2005.03.011
Sharp CD, Hines I, Houghton J, Warren A, Jackson TH, Jawahar A, Nanda A, Elrod JW, Long A, Chi A, Minagar A, Alexander JS (2003) Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am J Physiol-Heart Circulatory Physiol 285(6):H2592–H2598. https://doi.org/10.1152/ajpheart.00520.2003
Shibnev VA, Garaev TM, Finogenova MP, Shevchenko ES, Burtseva EI (2012) Some pathways to overcoming drug resistance of influenza a virus to adamantane derivatives. Pharm Chem J 46(1):1–5. https://doi.org/10.1007/s11094-012-0723-2
Smith DG, Cappai R, Barnham KJ (2007) The redox chemistry of the Alzheimer’s disease amyloid β peptide. Biochim Biophys Acta BBA-Biomembranes 1768(8):1976–1990. https://doi.org/10.1016/j.bbamem.2007.02.002
Spilovska K, Zemek F, Korabecny J, Nepovimova E, Soukupa O, Windischd M, Kuca K (2016) Adamantane–a lead structure for drugs in clinical practice. Curr Med Chem 23(29):3245–3266. https://doi.org/10.2174/0929867323666160525114026
Tacutu R, Budovsky A, Yanai H, Fraifeld VE (2011) Molecular links between cellular senescence, longevity and age-related diseases–a systems biology perspective. Aging Albany NY 3(12):1178–1191. https://doi.org/10.18632/aging.100413
Tai KK, Truong DD (2013) Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global cerebral hypoxia and reperfusion. PLoS ONE 8(4):e60309. https://doi.org/10.1371/journal.pone.0060309
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39(1):44–84. https://doi.org/10.1016/j.biocel.2006.07.001
Varier KM, Sumathi T (2019) Hinokitiol offers neuroprotection against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells by downregulating mRNA expression of MAO/α-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes. Neurotox Res 35(4):945–954. https://doi.org/10.1007/s12640-018-9988-x
Voronin AP, Volkova TV, Ilyukhin AB, Trofimova TP, Perlovich GL (2018) Structural and energetic aspects of adamantane and memantine derivatives of sulfonamide molecular crystals: experimental and theoretical characterisation. CrystEngComm 20(25):3476–3489. https://doi.org/10.1039/C8CE00426A
Zeidán-Chuliá F, Salmina AB, Malinovskaya NA, Noda M, Verkhratsky A, Moreira JCF (2014) The glial perspective of autism spectrum disorders. Neurosci Biobehav Rev 38:160–172. https://doi.org/10.1016/j.neubiorev.2013.11.008
Zhao J, Peng L, Zheng W, Wang R, Zhang L, Yang J, Chen H (2015) Chemically bonding of amantadine with gardenamide a enhances the neuroprotective effects against corticosterone-induced insults in PC12 cells. Int J Mol Sci 16(9):22795–22810. https://doi.org/10.3390/ijms160922795
Zheng H, Fridkin M, Youdim M (2014) From single target to multitarget/network therapeutics in Alzheimer’s therapy. Pharmaceuticals 7(2):113–135. https://doi.org/10.3390/ph7020113
Acknowledgements
This work was supported by the Bulgarian National Science Fund (Project M/23-8). This work was supported by the Russian Foundation for Basic Research (project No. 19-53-18003).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
All the authors listed have contributed to conception, design, gathering, analysis, or interpretation of data, and have contributed to the writing and intellectual content of the article. All the authors gave informed consent to the submission of this manuscript.
Additional information
Handling editor: K. Aoyama.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tencheva, A., Liu, R., Volkova, T.V. et al. Synthetic analogues of memantine as neuroprotective and influenza viral inhibitors: in vitro and physicochemical studies. Amino Acids 52, 1559–1580 (2020). https://doi.org/10.1007/s00726-020-02914-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-020-02914-4